Compugen (CGEN) Competitors $1.31 -0.10 (-7.09%) Closing price 04:00 PM EasternExtended Trading$1.31 0.00 (-0.31%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. ANAB, VECT, MRVI, URGN, SANA, TYRA, PGEN, RLAY, OPT, and ORICShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include AnaptysBio (ANAB), VectivBio (VECT), Maravai LifeSciences (MRVI), UroGen Pharma (URGN), Sana Biotechnology (SANA), Tyra Biosciences (TYRA), Precigen (PGEN), Relay Therapeutics (RLAY), Opthea (OPT), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Compugen vs. AnaptysBio VectivBio Maravai LifeSciences UroGen Pharma Sana Biotechnology Tyra Biosciences Precigen Relay Therapeutics Opthea ORIC Pharmaceuticals AnaptysBio (NASDAQ:ANAB) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends. Is ANAB or CGEN more profitable? Compugen has a net margin of 2.67% compared to AnaptysBio's net margin of -289.75%. Compugen's return on equity of 2.62% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-289.75% -287.94% -37.25% Compugen 2.67%2.62%1.36% Which has preferable valuation & earnings, ANAB or CGEN? Compugen has lower revenue, but higher earnings than AnaptysBio. Compugen is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M6.25-$163.62M-$5.21-3.57Compugen$27.86M4.18-$18.75M-$0.16-8.16 Which has more volatility and risk, ANAB or CGEN? AnaptysBio has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, Compugen has a beta of 3.19, indicating that its stock price is 219% more volatile than the S&P 500. Does the MarketBeat Community believe in ANAB or CGEN? AnaptysBio received 66 more outperform votes than Compugen when rated by MarketBeat users. Likewise, 66.25% of users gave AnaptysBio an outperform vote while only 64.24% of users gave Compugen an outperform vote. CompanyUnderperformOutperformAnaptysBioOutperform Votes37566.25% Underperform Votes19133.75% CompugenOutperform Votes30964.24% Underperform Votes17235.76% Do analysts recommend ANAB or CGEN? AnaptysBio presently has a consensus target price of $35.11, suggesting a potential upside of 88.72%. Compugen has a consensus target price of $4.00, suggesting a potential upside of 206.51%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ANAB or CGEN? In the previous week, AnaptysBio had 1 more articles in the media than Compugen. MarketBeat recorded 1 mentions for AnaptysBio and 0 mentions for Compugen. AnaptysBio's average media sentiment score of 0.00 equaled Compugen'saverage media sentiment score. Company Overall Sentiment AnaptysBio Neutral Compugen Neutral Do institutionals and insiders hold more shares of ANAB or CGEN? 12.2% of Compugen shares are owned by institutional investors. 33.7% of AnaptysBio shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCompugen beats AnaptysBio on 10 of the 18 factors compared between the two stocks. Remove Ads Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$116.45M$2.89B$5.38B$7.21BDividend YieldN/A1.53%4.87%4.05%P/E Ratio65.2529.5222.9517.52Price / Sales4.18427.09356.0485.30Price / CashN/A168.6838.1634.64Price / Book1.793.456.273.81Net Income-$18.75M-$72.06M$3.21B$247.10M7 Day Performance-14.71%-12.56%-7.64%-7.26%1 Month Performance-22.32%-19.80%-2.57%-9.98%1 Year Performance-43.75%-33.67%3.91%-7.33% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen1.2085 of 5 stars$1.31-7.1%$4.00+205.3%-42.0%$116.90M$27.86M65.5070Gap DownANABAnaptysBio1.7791 of 5 stars$18.71+9.5%$35.11+87.7%-6.9%$573.78M$91.28M-3.08100Gap DownHigh Trading VolumeVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeMRVIMaravai LifeSciences4.4747 of 5 stars$2.24-1.3%$8.22+266.9%-75.6%$565.66M$259.19M-1.37610Options VolumeHigh Trading VolumeURGNUroGen Pharma3.0207 of 5 stars$11.90-1.9%$38.20+221.0%-22.9%$548.52M$90.40M-3.78200Gap DownSANASana Biotechnology2.7932 of 5 stars$2.42+4.8%$10.80+346.3%-85.0%$544.56MN/A-1.73380TYRATyra Biosciences1.8279 of 5 stars$10.65-0.4%$30.50+186.4%-52.8%$538.92MN/A-6.6120Analyst RevisionGap DownPGENPrecigen2.994 of 5 stars$1.82+0.6%$7.00+284.6%-4.3%$535.16M$3.93M-3.31190Gap DownRLAYRelay Therapeutics2.0642 of 5 stars$3.10+1.3%$19.80+538.7%-67.9%$525.52M$10.01M-1.19330Gap DownOPTOpthea0.7068 of 5 stars$3.41+7.2%$12.00+251.9%-13.7%$524.84M$87,666.000.008Short Interest ↑Gap UpORICORIC Pharmaceuticals4.0489 of 5 stars$7.37+4.8%$18.86+155.9%-53.8%$523.47MN/A-4.0580Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies AnaptysBio Alternatives VectivBio Alternatives Maravai LifeSciences Alternatives UroGen Pharma Alternatives Sana Biotechnology Alternatives Tyra Biosciences Alternatives Precigen Alternatives Relay Therapeutics Alternatives Opthea Alternatives ORIC Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGEN Stock Free CGEN Stock Alerts